An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus (RSV) for ...

Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., have described a next-generation vaccination technology ...

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending ...

The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against ...

Sanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.

Vermont has the second lowest state fatality rate in the US (146.4 per 100K; Hawaii 112.8/100K). Mississippi (463.1/100K) and Oklahoma (459.1/100K) have the highest rates. The US average is 306.7/100K ...

Population-based analyses of new vaccination programmes provide robust real-world evidence for post-licensure vaccine ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...

Recently, AIM announced a comprehensive deployment to integrate the DeepSeek large model, particularly in vaccine development ...

As a result of the recognition of the increased impact of these viruses, new vaccines and therapeutic options have been and ...